Expect to See Tirzepatide on Home Med Lists

July 2022

You’ll see patients coming in on the new injectable tirzepatide (Mounjaro)...the first “twincretin” for type 2 diabetes.

Think of it as similar to a glucagon-like peptide-1 (GLP-1) agonist...but it’s also a glucose-dependent insulinotropic polypeptide (GIP) agonist. More twincretins are in the works.

Both hormones are secreted in the gut in response to food...so the dual mechanism doesn’t seem to increase risk of hypoglycemia.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote